SIC
NPCE icon

SJS Investment Consulting’s Neuropace NPCE Stock Holding History

SJS Investment Consulting’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144 Buy
9
+1
+13% +$16 ﹤0.01% 2534
2026
Q1 		$106 Buy
+8
New +$120 ﹤0.01% 2126

Other funds holding NPCE

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
HFS
Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM

SJS Investment Consulting's NPCE Position: Q2 2026 in Review

SJS Investment Consulting increased its Neuropace (NPCE) stake by 13% in Q2 2026, buying an estimated $16 and bringing the position to 9 shares worth $144. The position accounts for ﹤0.01% of the portfolio, ranked #2534.

SJS Investment Consulting first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • SJS Investment Consulting held 9 shares of Neuropace worth $144 as of Q2 2026.
  • SJS Investment Consulting bought 1 Neuropace share in Q2 2026, an estimated $16.
  • Neuropace made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2534 holding.
  • SJS Investment Consulting first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.